news
Investigational COVID-19 vaccine tablet safely induces immune response in Phase I
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
List view / Grid view
Vaxart
news
First patient dosed in COVID-19 vaccine tablet clinical trial
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
news
Oral COVID-19 vaccine candidate to enter Phase I human trials
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
news
COVID-19 vaccine tablet induces systemic and mucosal immune responses
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
news
Emergent to assist in production of US COVID-19 vaccine candidates
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
